JLJonathan H. Lass

Jonathan H. Lass

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan H. Lass has a total of 224 co-authors. Here are the top co-authors by number of shared publications:

  • Loretta B. Szczotka-Flynn

    Department of Ophthalmology and Visual Sciences, Case Western Reserve University and University Hospitals Eye Institute, Cleveland, OH; and

    10 shared publications
  • Beth Ann Benetz

    Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine and University Hospitals Eye Institute, Cleveland, OH

    9 shared publications
  • Allison R. Ayala

    Jaeb Center for Health Research, Tampa, Florida

    6 shared publications
  • David D. Verdier

    Verdier Eye Center, Grand Rapids, MI

    6 shared publications
  • Harry J. Menegay

    Department of Ophthalmology and Visual Sciences, Case Western Reserve University, and University Hospitals Eye Institute, Cleveland, OH

    5 shared publications
  • Mark A. Terry

    Devers Eye Institute, Portland, Oregon

    5 shared publications

Latest Publications

  • Open Access

    A human pharmacogenomics approach provides insight into the pathogenesis and pathophysiology of steroid-induced ocular hypertension

    by Zeyuan Song, Satyabrata Pany, Shengru Guo, Arpan G. Mazumder, Tatsuo Itakura, Jonathan Huang, Evan Magarychoff, Anastasia Gurinovich, Penelope H. Benchek, W. Daniel Stamer, et al.

  • A Multicenter, Randomized, Double-Masked, Sham-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-on Corneal Crosslinking in Keratoconus Subjects 8 to 45 Years of Age: Baseline Endothelial Studies

    by Michael Wellington Belin, Janet COMT DeMarchi, Beth Ann Ma Benetz, Qian Wu, Abdus Sattar, Edward C. Parsons, Loretta B. Od Szczotka-Flynn, Jonathan H. Lass

    Purpose: Determine the correlation between central endothelial cell density (ECD) and keratoconus tomographic disease severity. Methods: A subcohort of 254 subjects (477 eyes) at 11 clinical sites enrolled in a phase III study of epithelium-on crosslinking in keratoconus (ages 15–45) underwent specular microscopy of the central endothelium OU at baseline before treatment. ECD was graded by 2 image analysts from a central image analysis reading center with adjudication if ECD differed by ≥5%. The correlation by linear regression between ECD with Pentacam Belin/Ambrósio display final “D,” Anterior Radius of Curvature (ARC), Minimal Corneal Thickness (MinCT), and Posterior Elevation a Thinnest Point (PETP) PTI was examined. Results: Approximately 66.9% were male and 33.1% were female. Baseline ECD was 2802 ± 285 cells/mm 2 (1868–3650 cells/mm 2 ). In bivariate correlation analysis, ECD negatively correlated with age (r = −0.19, P < 0.01); final “D” (r = −0.25, P < 0.01); and PETP (r = −0.23, P < 0.01). ECD was positively correlated with ARC (r = 0.20, P < 0.01) and MinCT (r = 0.19, P < 0.01). ECD significantly decreased with age (β = −8.89, P < 0.01), with increasing final “D” (β = −8.68, P < 0.01), increasing PETP (β = −1.86, P < 0.01), decreasing ARC (β = 60.95, P < 0.01), and decreasing MinCT (β = 1.33, P < 0.01). Although ECD decreased with increasing disease severity and age, it remained relatively high, with only 1 eye showing an ECD 2 . Conclusions: Increasing keratoconus tomographic severity results in a significant decrease in ECD. However, even in the most advanced stages, the ECD remains within physiological range.

  • Age-Related Changes in Endothelial Cell Density of the Central and Peripheral Corneal Endothelium

    by Robin C. Su, LeAnne H. Young, Beth Ann Benetz, Robert C. O'BRien, Tsun-Kang Chiang, Pravamaya Das, Winston L. Li, Ahmed F. Omar, Jonathan H. Lass

    Purpose: To determine peripheral corneal endothelial cell density (ECD) changes with age compared with central ECD changes. Methods: Seventy-five phakic subjects with normal corneas were stratified prospectively into 3 age groups (20–39, 40–59, and 60–79 years, n = 25/group). Specular microscopic images were captured of the central, mid-peripheral, and peripheral cornea (3, 4, and 4.5 mm from the center, with 6, 4, and 2 targets, respective to the diameter). ECD was graded by 2 image analysts from a reading center at all locations with adjudication if ECD differed between the 2 graders >5%. Results: Central, mid-peripheral, and peripheral mean ECD decreased significantly with age. Central mean ECD decreased by 83 cells/mm 2 per decade ( P = 0.008). Mid-peripheral to peripheral mean ECD decreased by 86, 92, and 83 cells/mm 2 at 3, 4, and 4.5 mm from the center, respectively, per decade increase in age ( P = 0.003, 0.002, and 0.006, respectively). Estimated mean ECD differences by location for all participants showed an increase in ECD at 3 mm compared with the center and 4.5 mm (ECD greater by 91 and 102 cells/mm 2 , P 's < 0.001, respectively), as well as ECD at 4 mm compared with the center and 4.5 mm (ECD greater by 80 and 91 cells/mm 2 , P = 0.003 and <0.001, respectively). Conclusions: Central, mid-peripheral, and peripheral corneal ECD decreases significantly with age. There appears to be higher ECDs at 3 mm and 4 mm from the center, varying with age. These normative data could be useful in evaluating peripheral endothelial changes longitudinally in endothelial disease and surgery.


  • Open Access

    National Eye Institute Supported Randomized Controlled Trials in Keratoplasty for Endothelial Disorders: Lessons Learned

    by Ahmed F. Omar, Loretta B. Szczotka-Flynn, Beth Ann Benetz, Jonathan Carcione, Jonathan H. Lass

    National Eye Institute (NEI)–funded randomized controlled trials (RCTs) have significantly shaped the modern landscape of keratoplasty for endothelial disorders. Unlike retrospective studies, RCTs have offered the highest level of clinical evidence and have addressed critical questions related to histocompatibility matching, donor and donor tissue characteristics, donor tissue storage, and operative and postoperative factors supporting postoperative endothelial cell health. These RCTs have in turn directly influenced eye banking and keratoplasty practices. The purpose of this review is to 1) summarize the major findings from all of the NEI-sponsored keratoplasty RCTs, including the Collaborative Corneal Transplantation Studies, the Cornea Donor Study and its ancillary study, the Specular Microscopy Ancillary Study, the Cornea Preservation Time Study, as well as the on-going Diabetes Endothelial Keratoplasty Study and the Descemet Endothelial Thickness Comparison Trial; 2) review select keratoplasty RCTs not supported by the NEI; 3) compare findings from these RCTs with those from the major keratoplasty registries; and 4) discuss promising future directions in keratoplasty and eye banking that would lend themselves for RCTs. Collectively, these RCTs have clarified long-standing controversies, validated emerging practices, and will continue to provide the foundation for future innovation in the surgical management of endothelial diseases.

  • Diabetes Endothelial Keratoplasty Study: Methods and Impact on the Use of Corneas From Donors With Diabetes for Descemet Membrane Endothelial Keratoplasty

    by Marianne O. Price, Loretta B. Szczotka-Flynn, Colleen E. Bauza, Zachariah W. Reed, Beth Ann Benetz, Mark A. Greiner, David D. Verdier, Mark C. Soper, Michael S. Titus, Vincent M. Monnier, et al.

    Purpose: Describe aims, methods, characteristics of donors, donor corneas and recipients, and potential impact of the Diabetes Endothelial Keratoplasty Study (DEKS). Methods: The DEKS is a randomized, clinical trial to assess graft success and endothelial cell density (ECD) 1 year after Descemet membrane endothelial keratoplasty (DMEK) using corneas from donors with versus without diabetes in a 1:2 minimization assignment. Diabetes severity in the donor is assessed by medical history, postmortem HbA1c, and donor skin advanced glycation end-products and oxidation markers. A central image analysis reading center assesses baseline donor, 1-month and 1-year postoperative ECD. Results: The DEKS used corneas from 1154 donors for 1421 DMEK procedures on 1097 participants (324 bilateral) at 28 clinical sites. Forty-eight tissue preparations failed (3%). Mean donor age was 65 years; mean eye bank–determined screening ECD was 2709 cells/mm 2 . Ultimately, 106 (9%) of 1154 donors without diabetes history were classified as diabetic based on postmortem HbA1c ≥6.5%, and 509 (36%) of 1421 donor lenticules were classified as coming from diabetic donors. Recipients were 58% female, 96% White, and 53% phakic. Study eyes were treated for Fuchs endothelial corneal dystrophy (96%), pseudophakic corneal edema (2%), and failed endothelial keratoplasty (2%). Mean recipient age was 70 years; 21% had diabetes history and 26 (2%) had central laboratory determined HbA1c ≥6.5% without diabetes history. Conclusions: The DEKS will increase understanding of factors related to DMEK success while determining whether diabetes and/or diabetes severity in the donor and/or recipient adversely affects graft success and endothelial cell loss.


  • Open Access

    Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy

    by Charles C Lin, Winston Chamberlain, Beth Ann Benetz, William Gensheimer, Jennifer Y Li, Bennie H Jeng, Jameson Clover, Nicole Varnado, Sarah Abdelrahman, Amrita Srinivasan, et al.

    Introduction: It remains uncertain whether Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping only (DSO) yields better outcomes in patients with symptomatic Fuchs endothelial corneal dystrophy (FECD). This paper presents the protocol for the Descemet Endothelial Thickness Comparison Trial II (DETECT II), a multicentre, outcome-masked, randomised, placebo-controlled, clinical trial comparing DMEK to DSO with ripasudil (DSO-R) for this patient population. Methods and analysis: A total of 60 patients with endothelial dysfunction due to symptomatic FECD will be enrolled from seven participating sites in the USA. The patients will be randomly assigned in a 1:1 ratio to one of the following treatment groups: group 1—DMEK plus topical placebo and group 2—DSO plus topical ripasudil 0.4%. The enrolment period is 24 months. The primary outcome is best spectacle-corrected visual acuity at 12 months. Secondary outcomes include peripheral and central endothelial cell density, visual acuity, vision-related quality of life and Pentacam Scheimpflug tomography. Study outcomes will be analysed using mixed effects linear regression. Adverse events, including rebubble procedures, endothelial failure and graft rejection, will be documented and analysed using appropriate statistical methods. DETECT II aims to provide evidence on the comparative effectiveness of DMEK and DSO-R. The results of this trial will contribute to optimising the treatment of FECD, while also exploring the cost-effectiveness of these interventions. Dissemination of findings through peer-reviewed publications and national/international meetings will facilitate knowledge translation and guide clinical practice in the field of corneal transplantation. Ethics and dissemination: A data and safety monitoring committee has been empanelled by the National Eye Institute. All study protocols will be subject to review and approval by WCG IRB as the single IRB of record. This study will comply with the National Institute of Health (NIH) Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. Data from the trial will be made available on reasonable request. Trial registration number: NCT05275972.


  • Deep learning segmentation of endothelial cell images using an active learning paradigm with guided label corrections

    by Naomi Joseph, Ian Marshall, Elizabeth Fitzpatrick, Harry J. Menegay, Jonathan H. Lass, Beth Ann M. Benetz, David L. Wilson

    PurposeTo create Guided Correction Software for informed manual editing of automatically generated corneal endothelial cell (EC) segmentations and apply it to an active learning paradigm to analyze a diverse set of post-keratoplasty EC images.ApproachAn original U-Net model trained on 130 manually labeled post-Descemet stripping automated endothelial keratoplasty (EK) images was applied to 841 post-Descemet membrane EK images generating “uncorrected” cell border segmentations. Segmentations were then manually edited using the Guided Correction Software to create corrected labels. This dataset was split into 741 training and 100 testing EC images. U-Net and DeepLabV3+ were trained on the EC images and the corresponding uncorrected and corrected labels. Model performance was evaluated in a cell-by-cell analysis. Evaluation metrics included the number of over-segmentations, under-segmentations, correctly identified new cells, and endothelial cell density (ECD).ResultsUtilizing corrected segmentations for training U-Net and DeepLabV3+ improved their performance. The average number of over- and under-segmentations per image was reduced from 23 to 11 with the corrected training set. Predicted ECD values generated by networks trained on the corrected labels were not significantly different than the ground truth counterparts (p=0.02, paired t-test). These models also correctly segmented a larger percentage of newly identified cells. The proposed Guided Correction Software and semi-automated approach reduced the time to accurately segment EC images from 15 to 30 to 5 min, an ∼80% decrease compared to manual editing.ConclusionsGuided Correction Software can efficiently label new training data for improved deep learning performance and generalization between EC datasets.


  • Trends in Ophthalmological Patents, 2005–2020

    by Alison Zhao, Chandruganesh Rasendran, Supriya Aryal, James Yu, Raoul R. Wadhwa, Jonathan H. Lass

    Purpose: Technological development drives the optimization of therapeutics in ophthalmology, but quantifiable and systematic review of such innovation is lacking. To fill this gap, we characterize trends in ophthalmology-related patents in the United States from 2005 to 2020. Methods: Publicly available patent data from the US Patent and Trademark Office was analyzed with the R programming language. Ophthalmology-related patents were identified with a keyword search of their titles and claims text. Temporal trends were assessed with the Mann–Kendall trend test (α = 0.05, two-sided). Results: Of 4.5 million collected patents, some 21,000 (0.5%) were ophthalmology related. The number of annually granted ophthalmology patents increased over time (Mann–Kendall test: z = 4.91; P < 0.001), from 619 patents released in 2005 to 2,019 patents in 2020. Patent counts also increased over time for all ophthalmic subspecialties except oculoplastics, with steepest rises in retina (z = 4.91; P < 0.001) and cornea (z = 4.64; P < 0.001). The most cited patents were in biocompatible intraocular implants and implantable controlled-release drug delivery systems, which underscores particular advancement in therapeutic efficacy and safety in devices used in the treatment and management of common yet debilitating eye conditions. Conclusion: This exploratory analysis reveals hotspots for ophthalmology-related innovation in the United States that may predict current and future growth trends in device development and pharmacologic advancement in ophthalmology, paving the way for more diverse and effective treatment options for preserving vision.


  • Open Access

    Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma

    by Iqbal Ike K. Ahmed, Arsham Sheybani, Ticiana De Francesco, Jonathan H. Lass, Beth Ann Benetz, Thomas W. Samuelson, Dale Usner, L. Jay Katz


  • Reply

    by Jonathan H. Lass